- Active not recruitingPHASE2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
This study looks at new drug combinations for kidney cancer that has spread or can't be removed. It compares different immune-boosting medicines with a drug called axitinib to see how safe and effective they are.
For: Renal Cell CarcinomaUnited States · Australia · China - Active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
For: Advanced Malignancies · NSCLC · Ovarian CancerUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
This study looks at new treatments for advanced kidney cancer. It compares a combination of two drugs, pembrolizumab and axitinib, with a standard drug, sunitinib, to see which works better and is safer for people newly diagnosed with advanced kidney cancer.
For: Metastatic renal cell carcinomaIreland · Hungary · Czechia